

**Information Guide for Cancer Center Support Grant (CCSG) Non-Competing  
Progress Reports  
May 31, 2023**

The purpose of this document is to outline the information required by the Office of Cancer Centers (OCC) and the Office of Grants Administration (OGA) for evaluating a cancer center’s annual progress. All Research Performance Progress Reports (RPPR) forms should be used as relevant. Additional information and resources on the RPPR, including the current RPPR Instruction Guide and training archives, can be found at: <http://grants.nih.gov/grants/RPPR/>. Please note chapters 6 (Sections A – H) and 7 (Section 7.6) specifically apply to the P30 mechanism. RPPRs and eData files must be submitted two months (60 days) prior to the start of their next budget period.

**This information applies to applications submitted under PAR-20-043 and PAR-21-321. (For PAR-20-0431, the Plan to Enhance Diversity Component is not applicable.)**

BUDGET	Complete a budget page for each component requesting CCSG funds. Prior approval by NCI is required to reallocate more than 25% of the funds in any component to other components.
DIRECTOR’S OVERVIEW/6 ESSENTIAL CHARACTERISTICS	Discuss major accomplishments, changes, updates, and any issues noted in the previous review that were addressed. Include a copy of Data Table 1.
SUPPLEMENTS	See RPPR 6.B.3. List and summarize all P30 supplements. See RPPR 6.7 Section G1. In the Director’s Overview create a single PDF document that includes all supplements and their corresponding budget page, providing sufficient detail for NCI staff to evaluate progress. HSS Inclusion Records - If Development Funds were used to support clinical trials, the Center must report inclusion in planned enrollment reports (See RPPR 6.7. G4b 1.).
ADMINISTRATION	Discuss changes; if no changes occurred, a narrative is not required
LEADERSHIP, PLANNING, AND EVALUATION	Leadership: Discuss changes; if no changes occurred, a narrative is not required. Provide biosketches and other support as appropriate.  Planning and Evaluation: Discuss accomplishments. Provide a list of EAB members and include biosketches for new members.
DEVELOPMENTAL FUNDS	Discuss how Developmental Funds were used in the prior year and future plans for these funds. Remember that Developmental Funds are restricted and cannot be reallocated to other components.

	HSS Inclusion Records - If Development Funds were used to support clinical trials, the Center must report inclusion in planned enrollment reports (See RPPR 6.7. G4b 1.).
COMMUNITY OUTREACH AND ENGAGEMENT	Provide a concise description of accomplishments, changes, and future plans.
CANCER RESEARCH CAREER ENHANCEMENT AND RELATED ACTIVITIES	Provide a concise description of accomplishments, changes, and future plans. Include a copy of DT2A for training grants. <b>Do NOT include training grants in DT2A and 2B.</b>
PLAN TO ENHANCE DIVERSITY	Provide a concise description of accomplishments, changes, and future plans. <b>(Not applicable for PAR-20-043).</b>
RESEARCH PROGRAMS	Provide a concise description of accomplishments, changes, and future plans. Attach a list of relevant publications (maximum of 25 to be added in section B2). Major changes to research programs (i.e., deletion, revision, re-organization, re-alignment, etc.) require prior NCI approval and should be reported in detail.
PUBLICATIONS	See RPPR 6.3 Section C.1. Include publications resulting from work using CCSG funds (e.g., Developmental Funds, and direct funding support from a shared resource.)
SHARED RESOURCE MANAGEMENT & INDIVIDUAL SHARED RESOURCES	Discuss changes in Shared Resource Management and all individual CCSG Shared Resources (no publications required). If no changes occurred, a narrative is not required. If a Center terminates individual Shared Resources and allocates funds to other Shared Resources, including for the development of new Shared Resources, NCI prior approval is needed. HSS Inclusion Records - If Shared Resource funds were used to support clinical studies, the Center must report inclusion in planned enrollment reports (See RPPR 6.7.G4b 1.).
CLINICAL PROTOCOL AND DATA MANAGEMENT	Discuss updates and changes. If no changes occurred, a narrative is not required.
DATA SAFETY MONITORING (DSM)	Discuss updates and changes. If no changes occurred, a narrative is not required. Major changes (excluding personnel changes) to the DSM plan need to be reported to the Office of Cancer Centers (OCC). The revised plan should be submitted to OCC for review and approval.
HUMAN SUBJECTS/HUMAN SUBJECTS SYSTEM (HSS)	See RPPR 6. G.4

PROTOCOL REVIEW AND MONITORING SYSTEM (PRMS)	Discuss updates and changes. If no changes occurred, a narrative is not required. For conditionally satisfactory or unsatisfactory PRMS, discuss efforts to address deficiencies.
ALL PERSONNEL REPORT	See RPPR 6.4D & 7.6.D.1
DATA TABLES	Concurrent with submission of the RPPR, submit Data Tables 1-3 and DT4 (for non-interventional trials) as eData. Also, submit the CTRP-generated DT4 (pdf and excel) for interventional trials to <a href="mailto:ccsgdata@mail.nih.gov">ccsgdata@mail.nih.gov</a>